Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

SAN CARLOS, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of two late breaking posters at ObesityWeek® 2025 in Atlanta, Georgia.

Read more at globenewswire.com